Alumis ALMS
NASDAQ ALMS
$23.96 +0.93 (+4.04%)
At close: Aug 25, 2026 · 4:00 PM EDT

Alumis (ALMS) Return on Sales (2025 - 2026)

Alumis (ALMS) posted quarterly Return on Sales of 0.48% for Q4 2025, up 10.17% quarter-over-quarter from 0.54% in Q3 2025.

Alumis (ALMS) Return on Sales (2025 - 2026) Analysis & Trends

Alumis (ALMS) has reported Return on Sales for 1 consecutive years, with 0.48% the latest figure, recorded in Q4 2025.

  • In Q4 2025, Return on Sales changed N/A year-over-year to 0.48%; the TTM figure through Dec 2025 stood at 0.1% (changed N/A YoY), while the FY2025 annual figure was 0.1%, changed N/A from the prior year.
  • Return on Sales improved to 0.48% in Q4 2025 per ALMS's latest filing, from 0.54% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.22% in Q2 2025 and bottomed at 0.54% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Vertex Pharmaceuticals 140.32 Bn 132.47 Bn 2.84 Bn 0.00%
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 0.00%
3 Argenx Se 63.35 Bn 58.16 Bn 1.37 Bn 0.00%
4 Moderna 63.15 Bn 58.01 Bn 52.00 Mn -0.05%
5 BeOne Medicines 41.96 Bn 36.86 Bn 1.53 Bn 0.00%
6 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn 0.00%
7 Royalty Pharma 27.67 Bn 26.83 Bn - 0.00%
8 BioNTech SE 27.52 Bn 9.13 Bn 668.28 Mn 0.00%
9 Insmed 26.98 Bn 25.82 Bn 358.27 Mn 0.00%
10 Alumis 3.06 Bn 2.56 Bn - -0.86%

Historic Data

Download Data
DateValue
Jun 30, 2026 -0.86%
Dec 31, 2025 -0.48%
Sep 30, 2025 -0.54%
Jun 30, 2025 0.22%
Mar 31, 2025 -0.06%